Summaries & Associations of Study Results
TR-372 3,3'-Dimethoxybenzidine Dihydrochloride
Target Organs and Levels of Evidence
NTP Technical Report Number 372
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| 3,3'-DIMETHOXYBENZIDINE DIHYDROCHLORIDE 20325-40-0 |
06/27/89 | PRODUCTION OF DYES | Dosed-Water R: 0,80,170,330 PPM /70,45,75,70 PER GROUP RESPECTIVELY | Hazleton (Vienna) |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: CLEAR EVIDENCE | SKIN: BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60 | |||
| LIVER: NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60 | ||||
| INTESTINES: ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60 | ||||
| ORAL CAVITY: SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60 | ||||
| ZYMBAL GLAND: ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60 | ||||
| PREPUTIAL GLAND: ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59 | ||||
| MESOTHELIUM (ABDOMINAL CAVITY/TUNICA VAGINALIS): MESOTHELIOMA 2/60 1/45 7/75 6/60 | ||||
| MAY HAVE BEEN RELATED: | BRAIN: ASTROCYTOMA 0/60 2/44 3/75 1/60 | |||
| NON-NEOPLASTIC LESIONS: | SPLEEN: HEMATOPOIETIC CELL PROLIFERATION 3/60 13/42 43/74 38/59 | |||
| LUNG: INFILTRATION, CELLULAR, HISTIOCYTIC 0/60 3/44 10/75 6/60 | ||||
| HEART: ATRIUM, THROMBUS 3/60 15/44 27/75 23/60 | ||||
| LIVER: DEGENERATION, CYSTIC 13/60 23/45 34/74 28/60; DEGENERATION, CENTRILOBULAR, DIFFUSE 0/60 4/45 9/74 10/60; NECROSIS, CENTRILOBULAR 4/60 13/45 10/74 6/60 | ||||
| FR: CLEAR EVIDENCE | ZYMBAL GLAND: ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60 | |||
| CLITORAL GLAND: ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55 | ||||
| MAMMARY GLAND: ADENOCARCINOMA 1/60 2/45 14/75 20/60 | ||||
| SKIN: SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60 | ||||
| ORAL CAVITY: SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60 | ||||
| INTESTINES: ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60 | ||||
| LIVER: NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60 | ||||
| UTERUS/CERVIX: ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59 | ||||
| NON-NEOPLASTIC LESIONS: | LUNG: INFILTRATION, CELLULAR, HISTIOCYTIC 0/60 3/45 4/75 18/60 | |||
| LIVER: DEGENERATION, CYSTIC 1/60 2/44 1/75 5/60; DEGENERATION, CENTRILOBULAR 1/60 3/44 8/75 5/60; NECROSIS CENTRILOBULAR 1/60 2/44 6/75 5/60 | ||||
| SPLEEN: HEMATOPOIETIC CELL PROLIFERATION 3/60 22/44 50/75 47/60 | ||||
Web page last updated on February 10, 2006
